Drug intelligence / Profile preview

PC-0083

Development stage: Preclinical
Lead developer: Changtai Pharmaceutical
Modality: Small Molecules
Administration: Intramuscular

Overview

PC-0083 is a long-acting injectable microsphere formulation of valproate sodium, a small molecule antiepileptic drug developed by Changtai Pharmaceutical (PharmaMax Corp). It is designed for the treatment of epilepsy, utilizing sustained-release microsphere technology to maintain therapeutic drug levels over an extended period. This formulation aims to improve patient compliance and reduce the side effects associated with the peak-and-trough fluctuations of traditional oral valproate therapy. PC-0083 is currently in the development pipeline for antiepileptic therapy.

Other names: Valproate sodium long-acting injectionValproate sodium microspheresValproic acid microspheres

Targets

CaV3 (Caveolin-3)ABAT (4-aminobutyrate aminotransferase)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on PC-0083.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-0083.

Explore the full profile